Sugi Predict

Sugi Predict / Compounds / SCHEMBL7162130

SCHEMBL7162130

SCHEMBL7162130

O=C(OCc1ccccc1)n1ccc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ TSHR P16473 1/20 0.53
▸ NOTUM Q6P988 1/20 0.51
▸ P2RX4 Q99571 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ P2RX1 P51575 1/20 0.46
▸ P2RX3 P56373 1/20 0.46
▸ HTR3E A5X5Y0 1/20 0.45
▸ HTR3B O95264 1/20 0.45
▸ CHRNB2 P17787 1/20 0.45
▸ CHRNA7 P36544 1/20 0.45
▸ CHRNA4 P43681 1/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ HTR3D Q70Z44 1/20 0.45
▸ HTR3C Q8WXA8 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7168990 0.88 P2RX4 (0.50) L3MBTL1RAB9ATSHRNOTUMP2RX4
SCHEMBL7167672 0.88 P2RX4 (0.50) L3MBTL1RAB9ATSHRNOTUMP2RX4
SCHEMBL7163776 0.86 P2RX4 (0.52) L3MBTL1RAB9ATSHRNOTUMP2RX4
SCHEMBL7169790 0.85 LMNA (0.44) L3MBTL1RAB9AP2RX4ALDH1A1KMT2A
SCHEMBL7162470 0.85 RAB9A (0.50) L3MBTL1RAB9ATSHRNOTUMP2RX4
SCHEMBL7166112 0.83 TFPI2 (0.44) L3MBTL1RAB9AP2RX4ALDH1A1KMT2A
SCHEMBL14059899 0.83 KMT2A (0.47) RAB9AP2RX4ALDH1A1KMT2AMEN1
SCHEMBL6171436 0.83 ALDH1A1 (0.45) L3MBTL1P2RX4ALDH1A1KMT2AMEN1
SCHEMBL7168508 0.83 FABP4 (0.43) L3MBTL1RAB9ATSHRP2RX4ALDH1A1
SCHEMBL7166408 0.83 TFPI2 (0.44) L3MBTL1RAB9AP2RX4ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106674222-B A kind of chiral tricyclic ketone amine compound and its synthetic method and application 华东师范大学 2019-05-17 — — CN claimed
JP-2002540192-A — — 2002-11-26 — — JP claimed
EP-1165511-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE GÖDECKE GMBH (DE) 2002-01-02 — — EP claimed
WO-2000058286-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE Gödecke GmbH (DE) 2000-10-05 — — WO claimed
US-20230313202-A1 Oligonucleotides Comprising Modified Nucleosides SOMALOGIC OPERATING CO., INC. (US) 2023-10-05 — — US disclosed
US-11578330-B2 Oligonucleotides comprising modified nucleosides SOMALOGIC OPERATING CO., INC. (US) 2023-02-14 — — US disclosed
US-11479550-B2 EP4 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2022-10-25 — — US disclosed
CN-109153646-B Pyridine dicarboxamide derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2022-08-02 — — CN disclosed
EP-3913058-A1 OLIGONUCLEOTIDES COMPRISING MODIFIED NUCLEOSIDES Somalogic, Inc. (US) 2021-11-24 — — EP disclosed
EP-3478843-B1 OLIGONUCLEOTIDES COMPRISING MODIFIED NUCLEOSIDES SOMALOGIC INC (US) 2021-08-04 — — EP disclosed
CN-108884070-B Pyridyl derivatives as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2021-07-02 — — CN disclosed
US-20210171951-A1 Oligonucleotides Comprising Modified Nucleosides SOMALOGIC, INC. (US) 2021-06-10 — — US disclosed
US-9938314-B2 Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto SOMALOGIC, INC. (US) 2018-04-10 — — US disclosed
US-20160215013-A1 Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto SOMALOGIC OPERATING CO. INC. 2016-07-28 — — US disclosed
CN-1142162-C Bicyclic oxazolidinones as antibacterial agents �������Ŷ���Լ��������˾ 2004-03-17 — — CN disclosed
WO-2003048081-A2 GLYCINAMIDES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 — — WO disclosed
US-6566533-B1 Reacting aza-heterocyclic compounds (indoles and carbazoles) with alkyl- or aryl-halides in the presence of carbon dioxide and alkali carbonate WARNER-LAMBERT COMPANY LLC 2003-05-20 — — US disclosed
CN-1353709-A Bicyclic oxazolidinones as antibacterial agents PHARMACIA & UP JOHN CO (US) 2002-06-12 — — CN disclosed
EP-1165511-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE GÖDECKE GMBH (DE) 2002-01-02 — — EP disclosed
WO-2000058286-A2 METHOD OF PRODUCING HETEROCYCLIC CARBAMATES FROM AZA-HETEROCYCLIC COMPOUNDS AND CARBON DIOXIDE Gödecke GmbH (DE) 2000-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479550-B2 EP4 antagonist PTGER4, PTGER1, PTGER2 L3MBTL1 4047/4885RAB9A 3554/4885TSHR 409/4885
US-20160215013-A1 Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto NT5C3B, CDA, RNGTT L3MBTL1 2132/4885RAB9A 3516/4885TSHR 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.